Development of Ag-ZnO/AgO Nanocomposites Effectives for Leishmania braziliensis Treatment
Authors:
- Rafaela Miranda BarbosaRBRafaela Miranda Barbosa
- Malu Mateus Santos ObataMOMalu Mateus Santos Obata
- José Rodrigues Do Carmo NetoJNJosé Rodrigues Do Carmo Neto
- Rhanoica Oliveira GuerraRGRhanoica Oliveira Guerra
- Anna Victória Bernardes e BorgesABAnna Victória Bernardes e Borges
- Rafael Obata TrevisanRTRafael Obata Trevisan
- Letícia Cirelli RuizLRLetícia Cirelli Ruiz
- Júlia de Moura BernardiJBJúlia de Moura Bernardi
- Ana Carolina de Morais Oliveira-ScusselAOAna Carolina de Morais Oliveira-Scussel
- Sarah Cristina Sato Vaz TanakaSTSarah Cristina Sato Vaz Tanaka
- Fernanda Bernadelli de VitoFVFernanda Bernadelli de Vito
- Fernanda Rodrigues HelmoFHFernanda Rodrigues Helmo
Open Access
- 29 November 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2642
Abstract
Tegumentary leishmaniasis (TL) is caused by parasites of the genus Leishmania. Leishmania braziliensis (L.b) is one of the most clinically relevant pathogens that affects the skin and mucosa, causing single or multiple disfiguring and life-threatening injuries. Even so, the few treatment options for patients have significant toxicity, high dropout rates, high cost, and the emergence of resistant strains, which implies the need for studies to promote new and better treatments to combat the disease. Zinc oxide nanocrystals are microbicidal and immunomodulatory agents. Here, we develop new Ag-ZnO/xAgO nanocomposites (NCPs) with three different percentages of silver oxide (AgO) nanocrystals (x = 49%, 65%, and 68%) that could act as an option for tegumentary leishmaniasis treatment. Our findings showed that 65% and 68% of AgO inhibit the extra and intracellular replication of L.b. and present a high selectivity index. Ag-ZnO/65%AgO NCPs modulate activation, expression of surface receptors, and cytokine production by human peripheral blood mononuclear cells toward a proinflammatory phenotype. These results point to new Ag-ZnO/AgO nanocomposites as a promising option for L. braziliensis treatment.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG—Rede mineira de doenças infecciosas humanas e animais do estado de Minas Gerais)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Multi-User Laboratory of the Chemistry Institute of Federal University of Uberlândia
This publication has 57 references indexed in Scilit:
- The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasisCytokine, 2014
- CD4 T cell activation by B cells in human Leishmania (Viannia)infectionBMC Infectious Diseases, 2014
- Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen speciesInternational Journal of Nanomedicine, 2012
- The immunobiology of Leishmania braziliensis infectionFrontiers in Immunology, 2012
- New World cutaneous leishmaniasis: Updated review of current and future diagnosis and treatmentJournal of the American Academy of Dermatology, 2010
- Cytotoxicity and Immunological Response of Gold and Silver Nanoparticles of Different SizesSmall, 2009
- Cutaneous leishmaniasisThe Lancet Infectious Diseases, 2008
- T Cell Signalling Through CD73Cellular Signalling, 1997
- Tumor necrosis factor-α in human American tegumentary leishmaniasisMemórias do Instituto Oswaldo Cruz, 1996
- Susceptibility of leishmania to oxygen intermediates and killing by normal macrophagesJournal of Experimental Medicine, 1981